Alto Pharmacy vs Regeneron Pharmaceuticals
Side-by-side comparison of AI visibility scores, market position, and capabilities
Alto Pharmacy is a full-service digital pharmacy delivering prescriptions to patients with a tech-enabled experience that coordinates with providers and insurance.
About
Alto Pharmacy is a digital pharmacy company founded in 2015 that provides a tech-enabled prescription delivery experience for patients managing ongoing medications and specialty drugs. The company differentiates from traditional pharmacies through proactive care coordination, where pharmacy staff work with patients and prescribers to address insurance prior authorizations, copay assistance programs, and adherence support rather than requiring patients to navigate these barriers themselves. Alto serves both retail pharmacy customers and specialty pharmacy customers managing complex medications for conditions including fertility, oncology, HIV, and mental health. The company raised over $350M and delivers to patients in multiple major US metropolitan areas. Alto's platform integrates with electronic health record systems to receive prescriptions digitally and provides prescribers with real-time visibility into whether patients have filled their medications. The company has positioned its proactive, high-touch model as particularly valuable for specialty drugs where adherence, insurance navigation, and side effect management require more support than standard retail pharmacies provide. Alto Pharmacy serves as an alternative to incumbent pharmacy benefit managers for employers and health plans that want better specialty pharmacy management.
Regeneron (REGN) reported $13.9B revenue in FY2024, up 7% YoY. Top biotech company. Dupixent franchise >$14B. Leaders in eye disease, immunology, oncology. HQ: Tarrytown, NY.
About
Regeneron Pharmaceuticals, Inc. is a leading biotechnology company specializing in the discovery, development, and commercialization of medicines for serious diseases, headquartered in Tarrytown, New York. Founded in 1988 by Leonard Schleifer and George Yancopoulos, Regeneron developed its own proprietary drug discovery technology platform (VelociGene, VelocImmune) that has enabled the development of multiple breakthrough medicines. The company reported revenues of $13.9B in FY2024, up 7% year-over-year.
AI Visibility Head-to-Head
Key Details
Capabilities & Ecosystem
Capabilities
Integrations
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.